Free Trial
Tada emoji MarketBeat All Access — Now Just $5.00 for 5 Weeks
NASDAQ:IVVD

Invivyd Q2 2025 Earnings Report

Invivyd logo
$0.80 +0.01 (+0.79%)
Closing price 04:00 PM Eastern
Extended Trading
$0.76 -0.04 (-4.67%)
As of 07:52 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

Invivyd EPS Results

Actual EPS
-$0.12
Consensus EPS
-$0.04
Beat/Miss
Missed by -$0.08
One Year Ago EPS
N/A

Invivyd Revenue Results

Actual Revenue
N/A
Expected Revenue
$23.16 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Invivyd Announcement Details

Quarter
Q2 2025
Date
8/14/2025
Time
Before Market Opens
Conference Call Date
Wednesday, August 20, 2025
Conference Call Time
8:30AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

Invivyd's Q2 2025 Press ReleasePress Release
(8-K)
Invivyd's Q2 2025 Quarterly reportQuarterly report
(10-Q)

Invivyd Earnings Headlines

Invivyd Reports Second Quarter 2025 Financial Results and Recent Business Highlights
 |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/08/14/3133943/0/en/invivyd-reports-second-quarter-2025-financial-results-and-recent-business-highlights.html
Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19
 |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/08/14/3133942/0/en/invivyd-aligns-with-u-s-fda-on-rapid-pathway-to-full-approval-bla-of-vaccine-alternative-monoclonal-antibody-vyd2311-to-protect-american-adults-and-adolescents-from-covid-19.html
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.
August 14 at 2:00 AM  |  Porter & Company (Ad)
Invivyd (IVVD) to Release Earnings on Wednesday
August 12 at 2:47 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30271742
Scientist Dr. Akiko Iwasaki Joins SPEAR Study Group to Investigate Monoclonal Antibodies for Long COVID and COVID-19 Post-Vaccination Syndrome
July 23, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/23/3120107/0/en/scientist-dr-akiko-iwasaki-joins-spear-study-group-to-investigate-monoclonal-antibodies-for-long-covid-and-covid-19-post-vaccination-syndrome.html
National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population
July 21, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/07/21/3118612/0/en/national-comprehensive-cancer-network-nccn-guidelines-recommend-monoclonal-antibodies-for-covid-19-prevention-in-people-with-cancer-new-data-published-in-jama-oncology-underscore-s.html
See More Invivyd Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Invivyd? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Invivyd and other key companies, straight to your email.

About Invivyd

Invivyd (NASDAQ:IVVD), a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

View Invivyd Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles